Modelling BET inhibitor resistance in acute myeloid leukaemia

AML中表观遗传调控因子的突变不仅暗示了这些蛋白在AML中的致病作用，而且为治疗干预提供了潜在的靶点。在过去十年中出现的最有前途的表观遗传疗法之一是靶向溴域和额外末端（BET）蛋白家族的小分子抑制剂。这一建议将阐明对这类新药产生耐药性的细胞和分子机制

Mutations in epigenetic regulators in AML not only imply a causative role for these proteins in AML but also provide potential targets for therapeutic intervention. One of the most promising epigenetic therapies to have emerged in the last decade are small molecule inhibitors targeted to the Bromodomain and Extra Terminal (BET) family of proteins. This proposal will elucidate the cellular and molecular mechanisms that drive resistance to this new class of drugs